Waleed H. Hassanein Sells 4,000 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein sold 4,000 shares of the business’s stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $95.12, for a total value of $380,480.00. Following the completion of the sale, the chief executive officer now directly owns 74,087 shares of the company’s stock, valued at $7,047,155.44. The sale was disclosed in a legal filing with the SEC, which is available through this link.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $84.16 on Friday. TransMedics Group, Inc. has a twelve month low of $36.42 and a twelve month high of $99.63. The stock’s 50 day moving average price is $82.88 and its 200-day moving average price is $73.19. The company has a market capitalization of $2.75 billion, a PE ratio of -109.30 and a beta of 1.99. The company has a quick ratio of 8.49, a current ratio of 9.30 and a debt-to-equity ratio of 3.69.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Monday, February 26th. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.22. TransMedics Group had a negative return on equity of 2.35% and a negative net margin of 10.36%. The firm had revenue of $81.20 million for the quarter, compared to the consensus estimate of $68.49 million. During the same quarter in the previous year, the business earned ($0.21) EPS. The company’s revenue was up 158.6% compared to the same quarter last year. On average, equities analysts anticipate that TransMedics Group, Inc. will post -0.14 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on TMDX. Morgan Stanley lifted their price target on TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 28th. JPMorgan Chase & Co. lifted their price target on TransMedics Group from $87.00 to $105.00 and gave the company an “overweight” rating in a research note on Tuesday, February 27th. Piper Sandler began coverage on TransMedics Group in a research note on Thursday, March 28th. They set an “overweight” rating and a $95.00 price target for the company. Finally, Oppenheimer lifted their price target on TransMedics Group from $92.00 to $105.00 and gave the company an “outperform” rating in a research note on Tuesday, February 27th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $102.00.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Harbour Capital Advisors LLC boosted its stake in shares of TransMedics Group by 1.7% in the 4th quarter. Harbour Capital Advisors LLC now owns 8,371 shares of the company’s stock worth $627,000 after buying an additional 140 shares during the last quarter. First Horizon Advisors Inc. raised its holdings in shares of TransMedics Group by 45.1% in the 1st quarter. First Horizon Advisors Inc. now owns 544 shares of the company’s stock worth $41,000 after purchasing an additional 169 shares during the period. Belpointe Asset Management LLC raised its holdings in shares of TransMedics Group by 51.6% in the 1st quarter. Belpointe Asset Management LLC now owns 558 shares of the company’s stock worth $42,000 after purchasing an additional 190 shares during the period. RiverPark Advisors LLC raised its holdings in shares of TransMedics Group by 19.5% in the 4th quarter. RiverPark Advisors LLC now owns 1,319 shares of the company’s stock worth $104,000 after purchasing an additional 215 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of TransMedics Group by 2.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,512 shares of the company’s stock worth $896,000 after purchasing an additional 288 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.